Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
  • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
  • C07D495/04—Ortho-condensed systems
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P11/00—Drugs for disorders of the respiratory system
  • A61P11/06—Antiasthmatics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
  • A61P17/04—Antipruritics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
  • A61P17/06—Antipsoriatics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P19/00—Drugs for skeletal disorders
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P19/00—Drugs for skeletal disorders
  • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P27/00—Drugs for disorders of the senses
  • A61P27/02—Ophthalmic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
  • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
  • C07D491/04—Ortho-condensed systems

Definitions

• the present invention relates to 1,2-diaza-dibenzoazulene derivatives, to their pharmacologically acceptable salts and solvates, to processes and intermediates for the preparation thereof as well as to their antiinflammatory effects, especially to the inhibition of tumour necrosis factor- ⁇ (TNF- ⁇ ) production and the inhibition of interleukin-l (IL-1) production as well as to their analgetic action.
• TNF- ⁇ tumour necrosis factor- ⁇
• IL-1 interleukin-l
• aromatic dibenzoazulenes of pyrazole class with hydroxyalkyl, alkyloxy or aminoalkyloxy substituents on the pyrazole ring have not been prepared or disclosed so far. It is not known either that such compounds could possess an antiinflammatory action (inhibitors of TNF- ⁇ and IL-1 secretion) or analgetic action, which is an object of the present invention.
• TNF- ⁇ was defined as a serum factor induced by endotoxin and causing tumour necrosis in vitro and in vivo (Carswell EA et al., Proc. Natl. Acad. Sci. U.S.A., 1975, 72:3666-3670). Besides antitumour action, TNF- ⁇ also possesses numerous other biological actions important in the homeostasis of organisms and in pathophysiological conditions. The main sources of TNF- ⁇ are monocytes- macrophages, T-lymphocytes and mastocytes.
• Rheumatoid arthritis is an autoimmune chronic inflammatory disease characterized by irreversible pathological changes in the joints.
• TNF- ⁇ antagonists may also be used in numerous pathological conditions and diseases such as spondylitis, osteoarthritis, gout and other arthritic conditions, sepsis, septic shock, toxic shock syndrom, atopic dermatitis, contact dermatitis, psoriasis, glomerulonephritis, lupus erythematosus, scleroderma, asthma, cachexia, chronic obstructive lung disease, congestive cardiac arrest, insulin resistance, lung fibrosis, multiple sclerosis, Crohn's disease, ulcerative colitis, viral infections and AIDS.
• pathological conditions and diseases such as spondylitis, osteoarthritis, gout and other arthritic conditions, sepsis, septic shock, toxic shock syndrom, atopic dermatitis, contact dermatitis, psoriasis, glomerulonephritis, lupus erythematosus, scleroderma
• mice Some of the proofs indicating the biological importance of TNF- ⁇ were obtained by in vivo experiments in mice, in which mice gens for TNF- ⁇ or its receptor were inactivated. Such animals are resistant to collagen-induced arthritis (Mori L et al., J. Immunol, 1996, 757:3178-3182) and to endotoxin-caused shock (Pfeffer K et al., Cell, 1993, 73:457-467).
• TNF- ⁇ level In animal assays where TNF- ⁇ level was increased, a chronic inflammatory polyarthritis occured (Georgopoulos S et al., J.In ⁇ amm., 1996, 45:86-97; Keffer J et al, EMBO J., 1991, 70:4025-4031) and its pathological picture was alleviated by inhibitors of TNF- ⁇ production.
• the treatment of such inflammatory and pathological conditions usually includes the application of non- steroid antiinflammatory drugs and, in more severe cases, gold salts, D- penicillinamine or methotrexate are administered. Said drugs act symptomatically, but they do not stop the pathological process.
• Novel approaches in the therapy of rheumatoid arthritis are based upon drugs such as tenidap, leflunomide, cyclosporin, FK-506 and upon biomolecules neutralizing the TNF- ⁇ action.
• drugs such as tenidap, leflunomide, cyclosporin, FK-506 and upon biomolecules neutralizing the TNF- ⁇ action.
• etanercept Enbrel, Immunex/Wyeth
• infliximab Remicade, Centocor
• etanercept and infliximab are also registered for the therapy of Crohn's disease (Exp. Opin. Invest. Drugs, 2000, 9:103).
• IL-1 secretion is very important since IL-1 is an important cytokin in cell regulation and immunoregulation as well as in pathophysiological conditions such as inflammation (Dinarello CA et al., Rev. Infect. Disease, 1984, (5:51).
• Well-known biological activities of IL-1 are: activation of T-cells, induction of elevated temperature, stimulation of secretion of prostaglandine or collagenase, chemotaxia of neutrophils and reduction of iron level in plasma (Dinarello CA, J. Clinical Immunology, 1985, 5:287).
• Two receptors to which IL-1 may bind are well-known: IL-IRI and IL-IRII.
• IL-IRI transfers a signal intracellularly, whereas IL-IRII, though situated on the cell surface, does not transfer a signal inside the cell. Since IL1-RII binds IL-1 as well as IL1-RI, it may act as a negative regulator of IL-1 action. Besides this mechanism of signal transfer regulation, another natural antagonist of IL-1 receptor, IL-lra, is present in cells. This protein binds to IL-IRI, but does not bring about a stimulation thereof. The potency of IL-lra in stopping the signal transfer is not high and its concentration has to be 500 times higher than that of IL-1 in order to achieve a break in the signal transfer.
• the present invention relates to compounds 1,2-diaza-dibenzoazulenes of the formula I:
• Y and Z independently from each other denote one or more identical or different substituents linked to any available carbon atom, and may be halogen, C ⁇ -C 4 alkyl, C 2 -C alkenyl, C 2 -C 4 alkinyl, halo-C ⁇ -C 4 alkyl, hydroxy, C C alkoxy, trifluoromethoxy, - alkanoyl, amino, amino-C ⁇ -C 4 alkyl, 7V-(C ⁇ -C 4 alkyl)amino, NN-di(C ⁇ -C 4 alkyl)amino, thiol, C 1 -C 4 alkylthio, sulfonyl, C ⁇ -C 4 alkylsulfonyl, sulfinyl, C 1 -C 4 alkylsulfinyl, carboxy, C ⁇ -C 4 alkoxycarbonyl, cyano, nitro;
• R may be halogen, an optionally substituted heteroaryl or heterocycle, hydroxy, Ci- C 7 alkoxy, aryloxy, amino, N-(C r C 7 alkyl)amino, NN-di(C ⁇ -C 7 -alkyl)amino, (C ⁇ -C 7 alkyl)amino, amino-C ⁇ -C 7 alkoxy, C ⁇ -C 7 alkanoyl, aroyl, C1-C 7 alkanoyloxy, carboxy, an optionally substituted C ⁇ -C 7 alkyloxycarbonyl or aryloxycarbonyl, carbamoyl, N-(C 1 -C 7 -alkyl)carbamoyl, NN-di(C ⁇ -C 7 - alkyl)carbamoyl, cyano, nitro, or a substituent of the formula II
• R 3 and R 4 simultaneously or independently from each other may be hydrogen, C ⁇ -C 4 - alkyl, aryl or together with N have the meaning of an optionally substituted heterocycle or heteroaryl; m and n represent an integer from 0 to 3;
• Qi and Q 2 represent, independently from each other, oxygen, sulfur or groups: — ⁇ C X — — N
• substituents yi and y 2 independently from each other may be hydrogen, halogen, an optionally substituted C 1 -C 4 alkyl or aryl, hydroxy, C 1 -C 4 alkoxy, C ⁇ -C 4 alkanoyl, thiol,
• R 2 has the meaning of hydrogen, optionally substituted C r C 7 alkyl or aryl or a protecting group: formyl, C1-C 7 alkanoyl, C r C 7 alkoxycarbonyl, arylalkyloxycarbonyl, aroyl, arylalkyl, C 1 -C 7 alkylsilyl; as well as to pharmacologically acceptable salts and solvates thereof.
• halo halogen atom which may be fluorine, chlorine, bromine or iodine.
• alkyl relates to alkyl groups with the meaning of alkanes wherefrom radicals are derived, which radicals may be straight, branched or cyclic or a combination of straight and cyclic ones and branched and cyclic ones.
• the preferred straight or branched alkyls are e.g. methyl, ethyl, propyl, t-so-propyl, butyl, -sec-butyl and tert-butyl.
• the preferred cyclic alkyls are e.g. cyclopentyl or cyclohexyl.
• haloalkyl relates to alkyl groups which must be substituted with at least one halogen atom.
• the most frequent haloalkyls are e.g. chloromethyl, dichloromethyl, trifluoromethyl or 1,2-dichloropropyl.
• alkenyl relates to alkenyl groups having the meaning of hydrocarbon radicals, which may be straight, branched or cyclic or are a combination of straight and cyclic ones or branched and cyclic ones, but having at least one carbon-carbon double bond.
• the most frequent alkenyls are ethenyl, propenyl, butenyl or cyclohexenyl.
• alkinyl relates to alkinyl groups having the meaning of hydrocarbon radicals, which are straight or branched and contain at least one and at most two carbon-carbon triple bonds.
• the most frequent alkinyls are e.g. ethinyl, propinyl or butinyl.
• alkoxy relates to straight or branched chains of alkoxy group. Examples of such groups are methoxy, propoxy, prop-2-oxy, butoxy, but-2-oxy or methylprop-2- oxy.
• aryl relates to groups having the meaning of an aromatic ring, e.g. phenyl, as well as to fused aromatic rings.
• Aryl contains one ring with at least 6 carbon atoms or two rings with totally 10 carbon atoms and with alternating double (resonant) bonds between carbon atoms.
• the most freqently used aryls are e.g. phenyl or naphthyl.
• aryl groups may be linked to the rest of the molecule by any available carbon atom via a direct bond or via a C C alkylene group such as methylene or ethylene.
• heteroaryl relates to groups having the meaning of aromatic and partially aromatic groups of a monocyclic or bicyclic ring with 4 to 12 atoms, at least one of them being a hetero atom such as O, S or N, and the available nitrogen atom or carbon atom is the binding site of the group to the rest of the molecule either via a direct bond or via a C1-C 4 alkylene group defined earlier.
• heteroaryl examples of this type are thiophenyl, pyrrolyl, imidazolyl, pyridinyl, oxazolyl, thiazolyl, pyrazolyl, tetrazolyl, pirimidinyl, pyrazinyl, quinolinyl or triazinyl.
• heterocycle relates to five-member or six-member, completely saturated or partly unsaturated heterocyclic groups containing at least one hetero atom such as O, S or N, and the available nitrogen atom or carbon atom is the binding site of the group to the rest of the molecule either via a direct bond or via a C ⁇ -C alkylene group defined earlier.
• heteroatom such as O, S or N
• the most frequent examples are morpholinyl, piperidinyl, piperazinyl, pyrrolidinyl, pirazinyl or imidazolyl.
• alkanoyl relates to straight chains of acyl group such as formyl, acetyl or propanoyl.
• aroyl group relates to aromatic acyl groups such as benzoyl.
• alkyl relates to alkyl groups which may be optionally additionally substituted with one, two, three or more substituents.
• substituents may be halogen atom (preferably chlorine or fluorine), hydroxy, C1-C 4 alkoxy (preferably methoxy or ethoxy), thiol, C1-C 4 alkylthio (preferably methylthio or ethylthio), amino, N-(C ⁇ -C 4 ) alkylamino (preferably N-methylamino or N- ethylamino), N,N-di(C ⁇ -C 4 -alkyl)-amino (preferably dimethylamino or diethylamino), sulfonyl, C ⁇ -C 4 alkylsulfonyl (preferably methylsulfonyl or ethylsulfonyl), sulfinyl, C 1 -C 4 alkylsulfinyl (preferably methyls
• alkenyl relates to alkenyl groups optionally additionally substituted with one, two or three halogen atoms.
• substituents may be e.g. 2-chloroethenyl, 1,2-dichloroethenyl or 2-bromo-propene-l-yl.
• aryl, heteroaryl or heterocycle relates to aryl, heteroaryl or heterocyclic groups which may be optionally additionally substituted with one or two substituents.
• the substituents may be halogen (preferably chlorine or fluorine), C 1 -C 4 alkyl (preferably methyl, ethyl or isopropyl), cyano, nitro, hydroxy, C ⁇ -C 4 alkoxy (preferably methoxy or ethoxy), thiol, C ⁇ -C 4 alkylthio (preferably methylthio or ethylthio), amino, N-(C ⁇ -C 4 ) alkylamino (preferably N-methylamino or N-ethylamino), NN-di(C ⁇ -C -alkyl)-amino (preferably NN-dimethylamino or N,N- diethylamino), sulfonyl, C r C 4 alkylsulfonyl (preferably methyl
• R a relates to groups such as alkyl (preferably methyl or ethyl), alkanoyl (preferably acetyl), alkoxycarbonyl (preferably methoxycarbonyl or ter/-butoxycarbonyl), arylmethoxycarbonyl (preferably benzyloxycarbonyl), aroyl (preferably benzoyl), arylalkyl (preferably benzyl), alkylsilyl (preferably trimethylsilyl) or alky lsilylalkoxy alkyl (preferably trimethylsilylethoxymethyl).
• alkyl preferably methyl or ethyl
• alkanoyl preferably acetyl
• alkoxycarbonyl preferably methoxycarbonyl or ter/-butoxycarbonyl
• arylmethoxycarbonyl preferably benzyloxycarbonyl
• aroyl preferably benzoyl
• arylalkyl preferably benzyl
• alkylsilyl
• R 3 and R 4 together with N have the meaning of heteroaryl or heterocycle
• groups are morpholine-4-yl, piperidine-1-yl, pyrrolidine-1-yl, imidazole-1-yl or piperazine-1-yl.
• salts relate to salts of the compounds of the formula I and include e.g. salts with C ⁇ -C alkylhalides (preferably methyl bromide, methyl chloride) (quaternary ammonium salts), with inorganic acids (hydrochloric, hydrobromic, phosphoric, metaphosphoric, nitric or sulfuric acids) or with organic acids (tartaric, acetic, citric, maleic, lactic, fumaric, benzoic, succinic, methane sulfonic or -toluene sulfonic acids).
• C ⁇ -C alkylhalides preferably methyl bromide, methyl chloride
• inorganic acids hydroochloric, hydrobromic, phosphoric, metaphosphoric, nitric or sulfuric acids
• organic acids tartaric, acetic, citric, maleic, lactic, fumaric, benzoic, succinic, methane sulfonic or -toluene sulfonic acids
• Some compounds of the formula I may form salts with organic or inorganic acids or bases and these are also included in the present invention.
• Solvates which may be formed by compounds of the formula I or salts thereof are also an object of the present invention.
• the compounds of the formula I may have geometric isomers and one or more chiral centres so that there can exist enantiomers or diastereoisomers.
• the present invention also relates to such isomers and mixtures thereof including racemates.
• the present invention also relates to all possible tautomeric forms of particular compounds of the formula I.
• a further object of the present invention relates to the preparation of compounds of the formula I according to processes comprising
• L 1 has the meaning of a leaving group
• the compounds of the formula I, wherein R 1 has the meaning of CHO may be obtained by formylation of the compounds of the formula III, wherein R 2 has the meaning of a protecting group, by the action of n-butyl-lithium at a decreased temperature (preferably -80 °C) within up to half an hour, followed by the addition of NN-dimethylformamide and a continuation of the reaction at room temperature.
• the products may be isolated and purified by crystallization or chromatography on a silica gel column.
• compounds of the formula III may be prepared starting from enaminoketone dibenzo-oxepine or dibenzo-thiepine, which is a product of the reaction of the corresponding ketone and dimethyl-formamide-dimethylacetal (WO 98/52937).
• enaminoketone dibenzo-oxepine or dibenzo-thiepine which is a product of the reaction of the corresponding ketone and dimethyl-formamide-dimethylacetal (WO 98/52937).
• hydrazine and enaminoketone there may be prepared 1- or 2-substituted derivatives of the formula III, whereas by the reaction of hydrazine hydrate a nonsubstituted pyrazole ring of the formula IX is formed.
• the free NH group of the compounds of the formula IX may be protected by the reaction with compounds of the formula X
• L 2 has the meaning of a leaving group such as halogen (most frequently chlorine or bromine), whereat the product III in the form of an isomer mixture is formed.
• the reaction is carried out in organic solvents such as NN-dimethylsulfoxide, tetrahydrofuran, benzene or toluene under the addition of a strong base such as sodium hydride at an increased temperature from 50 °C to 150 °C during 1 to 5 hours.
• the crude product may be isolated and purified by recrystallization or chromatography on a silica gel column.
• the reaction is carried out at a temperature from 20°C to 100°C during 1 to 24 hours in a two-phase system (preferably with 50% NaOH/toluene) in the presence of a phase transfer catalyst (preferably benzyl triethyl ammonium chloride, benzyl triethyl ammonium bromide, cetyl trimethyl bromide).
• a phase transfer catalyst preferably benzyl triethyl ammonium chloride, benzyl triethyl ammonium bromide, cetyl trimethyl bromide.
• alcohols of the formula IV may be prepared from the compounds of the formula I, wherein R 1 has the meaning of a suitable functional group.
• alcohols of the formula IV may be obtained by the reduction of aldehyde, carboxyl or alkyloxycarbonyl group (e.g. methyloxycarbonyl or ethyloxycarbonyl) by using metal hydrides such as lithium aluminum hydride or sodium borohydride.
• metal hydrides such as lithium aluminum hydride or sodium borohydride.
• alcohols of the formula IV may be prepared by the hydrolysis of the corresponding esters in an alkaline or acidic medium.
• the starting compounds of the formula V are already known or are prepared according to methods disclosed for the preparation of analogous compounds.
• the starting compounds of the formula VI may be obtained by halogenation (e.g. bromination or chlorination) of compounds of the formula IV with usual halogenating agents ( hydrobromic acid, PBr 3 , SOCl 2 or PC1 5 ) by processes as disclosed in the literature.
• halogenation e.g. bromination or chlorination
• hydrobromic acid, PBr 3 , SOCl 2 or PC1 5 usual halogenating agents
• the starting compounds of the formula VII are already known or are prepared according to methods disclosed for the preparation of analogous compounds.
• the compounds of the formula I, wherein Qi has the meaning of -0-, -NH- or -S-, may be prepared by condensation of the compounds of the formula VIII and of compounds of the formula V, wherein L 1 has the meaning of a leaving group defined earlier.
• the reaction may be carried out at reaction conditions disclosed in method b) or under the conditions of reactions of nucleophilic substitution disclosed in the literature.
• the starting alcohols, amines and thiols may be obtained by a reaction of water, ammonia or hydrogen sulfide with compounds VI according to processes disclosed in the literature.
• the alcohols of the structure IV may be oxidized to corresponding compounds of the formula VIII, wherein Qi has the meaning of carbonyl and which may further, by reaction with corresponding ylide reagents, result in a prolongation of the chain and in the formation of an alkenyl substituent with carbonyl or ester groups as disclosed in HR patent application No. 20000310.
• the compounds of the formula I may be prepared by transforming other compounds of the formula I and it is to be understood that the present invention also comprises such compounds and processes.
• a special example of a change of a functional group is the reaction of the aldehyde group with chosen phosphorous ylides resulting in a prolongation of the chain and the formation of an alkenyl substituent with carbonyl or ester groups as disclosed in HR patent application No. 20000310. These reactions are carried out in solvents such as benzene, toluene or hexane at elevated temperature (most frequently at boiling temperature).
• Oxidation or reduction reactions are a further possibility of the change of substituents in the compounds of the formula I.
• Most frequently used oxidation agents are peroxides (hydrogen peroxide, m-chloroperbenzoic acid or benzoyl peroxide) or permanganate, chromate or perchlorate ions.
• peroxides hydrogen peroxide, m-chloroperbenzoic acid or benzoyl peroxide
• permanganate chromate or perchlorate ions.
• alkylsulf ⁇ nyl or alkylsulfonyl groups may be prepared.
• substituents of the aromatic structure in the compounds of the formula I may be introduced by standard substitution reactions or by usual changes of individual functional groups. Examples of such reactions are aromatic substitutions, alkylations, halogenation, hydroxy lation as well as oxidation or reduction of substituents. Reagents and reaction conditions are known from the literature. Thus e.g. by aromatic substitution a nitro group is introduced in the presence of concentrated nitric acid and sulfuric acid. By using acyl halides or alkyl halides, the introduction of an acyl group or an alkyl group is made possible. The reaction is carried out in the presence of Lewis acids such as aluminum- or iron-trichloride in conditions of Friedel-Craft reaction. By the reduction of the nitro group, an amino group is obtained, which is by a diazotizing reaction converted to a suitable starting group, which may be replaced with one of the following groups: H, CN, OH, Hal.
• a convenient protection for amino or alkylamino groups are groups such as e..g. alkanoyl (acetyl), alkoxycarbonyl (methoxycarbonyl, ethoxycarbonyl or tert- butoxycarbonyl); arylmethoxycarbonyl (benzyloxycarbonyl), aroyl (benzoyl) or alkylsilyl (trimethylsilyl or trimethylsilylethoxymethyl) groups.
• alkanoyl acetyl
• alkoxycarbonyl methoxycarbonyl, ethoxycarbonyl or tert- butoxycarbonyl
• arylmethoxycarbonyl benzyloxycarbonyl
• aroyl benzoyl
• alkylsilyl trimethylsilyl or trimethylsilylethoxymethyl
• acyl groups such as alkanoyl, alkoxycarbonyl or aroyl may be eliminated by hydrolysis in the presence of a base (sodium hydroxide or potassium hydroxide), t ⁇ rt-butoxycarbonyl or alkylsilyl (trimethylsilyl) may be eliminated by treatment with a suitable acid (hydrochloric, sulfuric, phosphoric or trifluoroacetic acid), whereas arylmethoxycarbonyl group (benzyloxycarbonyl) may be eliminated by hydrogenation using a catalyst such as palladium on carbon.
• a base sodium hydroxide or potassium hydroxide
• t ⁇ rt-butoxycarbonyl or alkylsilyl trimethylsilyl
• arylmethoxycarbonyl group benzyloxycarbonyl
• a catalyst such as palladium on carbon.
• Salts of the compounds of the formula I may be prepared by generally known processes such as e.g. by reacting the compounds of the formula I with a corresponding base or acid in an appropriate solvent or solvent mixture e.g. ethers (diethylether) or alcohols (ethanol, propanol or isopropanol).
• an appropriate solvent or solvent mixture e.g. ethers (diethylether) or alcohols (ethanol, propanol or isopropanol).
• Another object of the present invention concerns the use of the present compounds in the therapy of inflammatory diseases and conditions, especially all diseases and conditions induced by excessive TNF- ⁇ and IL-1 secretion.
• An effective dose of inhibitors of production of cytokins or inflammation mediators which are the object of the present invention, or pharmacologically acceptable salts thereof may be used in the production of drugs for the treatment and prophylaxis of any pathological condition or disease induced by excessive unregulated production of cytokins or inflammation mediators.
• the present invention specifically relates to an effective dose of TNF- ⁇ inhibitor, which may be determined by usual methods.
• the present invention further relates to a pharmaceutical formulation containing an effective non-toxic dosis of the present compounds as well as pharmaceutically acceptable carriers or solvents.
• the preparation of pharmaceutical formulations may include blending, granulating, tabletting and dissolving the ingredients.
• Chemical carriers may be solid or liquid. Solid carriers may be lactose, sucrose, talcum, gelatine, agar, pectin, magnesium stearate, fatty acids etc. Liquid carriers may be syrups, oils such as olive oil, sunflower oil or soya bean oil, water etc. Similarly, the carrier may also contain a component for a sustained release of the active component such as e.g. glyceryl monostearate or glyceryl distearate. Various forms of pharmaceutical formulations may be used.
• solid carrier there may be prepared tablets, hard gelatine capsules, powder or granules that may be administered in capsules per os.
• the amount of the solid carrier may vary, but it is mainly from 25 mg to 1 g. If a liquid carrier is used, the formulation would be in the form of a syrup, emulsion, soft gelatine capsules, sterile injectable liquids such as ampoules or non-aqueous liquid suspensions.
• Compounds according to the present invention may be applied per os, parenterally, locally, intranasally, intrarectally and intravaginally.
• the parenteral route herein means intravenous, intramuscular and subcutaneous applications.
• Appropriate formulations of the present compounds may be used in the prophylaxis as well as in the treatment of inflammatory diseases and conditions induced by an excessive unregulated production of cytokins or inflammation mediators, primarily TNF- ⁇ . They comprise rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis and other arthritic pathological conditions and diseases, eczemas, psoriasis and other inflammatory skin conditions, inflammatory eye diseases, Crohn's disease, ulcerative colitis and asthma.
• PBMC Human peripheral blood mononuclear cells
• the cells were incubated at 37°C in an atmosphere with 5% C0 2 and 90% humidity.
• a negative control the cells were cultivated only in the medium (NC)
• TNF- ⁇ secretion was triggered by adding 1 ng/ml of lipopolysaccharides (LPS, E. coli serotype 0111:B4, SIGMA) (PC).
• LPS lipopolysaccharides
• PC lipopolysaccharides
• TS lipopolysaccharides
• TS lipopolysaccharides
• the TNF- ⁇ level in the cell supernatant was determined by ELISA procedure according to the suggestions of the producer (R&D Systems).
• the test sensitivity was ⁇ 3pg/ml TNF- ⁇ .
• the IL-1 level was determined in an assay under the same conditions and with the same number of cells and the same concentration of the stimulus by ELISA procedure (R&D Systems).
• the percentage of inhibition of TNF- ⁇ or IL-1 production
• % inhibition [1- (TS-NC)/(PC-NC)] * 100.
• the IC 50 value was defined as the substance concentration, at which 50% of TNF- ⁇ production were inhibited.
• peritoneal macrophages Balb/C mouse strain males, age 8 to 12 weeks, were injected i.p. with 300 ⁇ g of zymosan (SIGMA) dissolved in a phosphate buffer (PBS) in a total volume of 0.1 ml/mouse. After 24 hours the mice were euthanized according to the Laboratory Animal Welfare Act. The peritoneal cavity was washed with a sterile physiological solution (5 ml). The obtained peritoneal macrophages were washed twice with a sterile physiological solution and, after the last centrifugation (350 g/10 min), resuspended in RPMI 1640, into which 10% of FBS portion were added.
• SIGMA zymosan
• PBS phosphate buffer
• TNF- ⁇ secretion 5x10 4 cells/well were cultivated in a total volume of 200 ⁇ l for 18 to 24 hours on microtitre plates with a flat bottom (96 wells, Falcon) in RPMI 1640 medium, into which 10% of fetal bovine serum (FBS, Biowhittaker) inactivated by heat, 100 units/ml of penicillin, 100 mg/ml of streptomycin, 20 mM HEPES and 50 ⁇ M 2-mercaptoethanol (all of GIBCO) were added. The cells were incubated at 37°C in an atmosphere with 5% C0 2 and 90%) humidity.
• FBS fetal bovine serum
• % inhibition [1- (TS-NC)/(PC-NC)] * 100.
• the IC 50 value was defined as the substance concentration, at which 50% of TNF- ⁇ production were inhibited.
• TNF- ⁇ or IL-1 secretion in mice was induced according to the already disclosed method (Badger AM et al., J. Pharmac. Env. Therap., 1996, 270:1453-1461).
• Balb/C males, age 8 to 12 weeks, in groups of 6 to 10 animals were used.
• the animals were treated p.o. either with a solvent only (in negative and in positive controls) or with solutions of substances 30 minutes prior to i.p. treatment with LPS (E. coli serotype 0111:B4, Sigma) in a dosis of 1-25 ⁇ g/animal. Two hours later the animals were euthanized by means of i.p.
• TNF- ⁇ level in the plasma was determined by ELISA procedure (Biosource, R&D Systems) according to the producer's instructions.
• the test sensitivity was ⁇ 3pg/ml TNF- ⁇ .
• the IL-1 level was determined by ELISA procedure (R&D Systems). The percentage of inhibition of TNF- ⁇ or IL-1 production was calculated by the equation:
• % inhibition [1- (TS-NC)/(PC-NC)] * 100.
• Active are the compounds showing 30% or more inhibition of TNF- ⁇ production at a dosis of 10 mg/kg.
• mice 30 minutes prior to i.p. application of acetic acid in a concentration of 0.6%, whereas test groups received standard (acetylsalicylic acid) or test substances in methyl cellulose p.o. 30 minutes prior to i.p. application of 0.6% acetic acid (volume 0.1 ml/10 g).
• test groups received standard (acetylsalicylic acid) or test substances in methyl cellulose p.o. 30 minutes prior to i.p. application of 0.6% acetic acid (volume 0.1 ml/10 g).
• the mice were placed individually under glass funnels and the number of writhings was registered for 20 minutes for each animal. The percentage of writhing inhibition was calculated according to the equation:
• % inhibition (mean value of number of writhings in the control group - number of writhings in the test group)/number of writhings in the control group * 100.
• Active are the compounds showing such analgetic activity as acetylsalicylic acid or better.
• mice Male Balb/C mice (Charles River, Italy), age 8 to 12 weks, were used.
• LPS isolated from Serratie marcessans (Sigma, L-6136) was diluted in sterile physiological solution. The first LPS injection was administered intradermally in a dosis of 4 ⁇ g/mouse. 18 to 24 hours later, LPS was administered i.v. in a dosis of 90-200 ⁇ g/mouse.
• a control group received two LPS injections as disclosed above. The test groups received substances p.o. half an hour prior to each LPS application. Survival after 24 hours was observed.
• Active are the substances at which the survival at a dosis of 30 mg/kg was 40% or more.
• reaction mixture was heated at boiling temperature for 5 hours, the solvent was evaporated under reduced pressure and the dry residue was dissolved in a mixture of water and dichloromethane.
• the organic product was extracted with dichloromethane and the crude product was purified by chromatography on a silica gel column, whereupon a crystalline product of a yellow colour was isolated.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• General Health & Medical Sciences (AREA)
• Veterinary Medicine (AREA)
• General Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Pharmacology & Pharmacy (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Public Health (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Pulmonology (AREA)
• Rheumatology (AREA)
• Physical Education & Sports Medicine (AREA)
• Dermatology (AREA)
• Ophthalmology & Optometry (AREA)
• Immunology (AREA)
• Orthopedic Medicine & Surgery (AREA)
• Pain & Pain Management (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Nitrogen Condensed Heterocyclic Rings (AREA)
• Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Priority Applications (8)

Applications Claiming Priority (2)

Publications (2)

Family

ID=29559973

Family Applications (1)

Country Status (15)

Cited By (4)

Citations (2)

Family Cites Families (16)

• 2002
  • 2002-05-23 HR HR20020452A patent/HRP20020452A2/hr not_active Application Discontinuation
• 2003
  • 2003-05-20 US US10/515,709 patent/US7550498B2/en not_active Expired - Fee Related
  • 2003-05-20 AU AU2003232368A patent/AU2003232368A1/en not_active Abandoned
  • 2003-05-20 RS YU100204A patent/RS100204A/sr unknown
  • 2003-05-20 WO PCT/HR2003/000022 patent/WO2003099822A2/en active IP Right Grant
  • 2003-05-20 EP EP03755234A patent/EP1587807B1/de not_active Expired - Lifetime
  • 2003-05-20 DE DE60321724T patent/DE60321724D1/de not_active Expired - Fee Related
  • 2003-05-20 AT AT03755234T patent/ATE398621T1/de not_active IP Right Cessation
  • 2003-05-20 CA CA002487015A patent/CA2487015A1/en not_active Abandoned
  • 2003-05-20 PL PL03374341A patent/PL374341A1/xx not_active Application Discontinuation
  • 2003-05-20 ES ES03755234T patent/ES2306888T3/es not_active Expired - Lifetime
  • 2003-05-20 CN CNA038167042A patent/CN1671712A/zh active Pending
  • 2003-05-20 JP JP2004507479A patent/JP2006500322A/ja active Pending
  • 2003-05-23 AR ARP030101803A patent/AR040039A1/es not_active Application Discontinuation
• 2004
  • 2004-11-29 IS IS7565A patent/IS7565A/is unknown

Patent Citations (2)

Non-Patent Citations (2)

Also Published As

Similar Documents

Legal Events